AR107708A1 - Formulaciones de antagonista de il-6 y sus usos - Google Patents
Formulaciones de antagonista de il-6 y sus usosInfo
- Publication number
- AR107708A1 AR107708A1 ARP170100456A ARP170100456A AR107708A1 AR 107708 A1 AR107708 A1 AR 107708A1 AR P170100456 A ARP170100456 A AR P170100456A AR P170100456 A ARP170100456 A AR P170100456A AR 107708 A1 AR107708 A1 AR 107708A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- formulation
- antibody
- container
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298774P | 2016-02-23 | 2016-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107708A1 true AR107708A1 (es) | 2018-05-23 |
Family
ID=59685584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100456A AR107708A1 (es) | 2016-02-23 | 2017-02-23 | Formulaciones de antagonista de il-6 y sus usos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190046642A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3419599A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2019510078A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180116359A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108718522A (cg-RX-API-DMAC7.html) |
| AR (1) | AR107708A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017223687A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018017031A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3012350A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018010032A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017147293A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2020121415A (ru) * | 2017-11-30 | 2021-12-30 | Био-Тера Солюшнз, Лтд. | Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6 |
| CN112739378B (zh) * | 2018-09-14 | 2025-05-06 | 田边三菱制药株式会社 | 含有人抗il-33单克隆抗体的医药用组合物 |
| BR112021008155A2 (pt) * | 2018-10-31 | 2021-08-10 | Richter Gedeon Nyrt. | formulação farmacêutica aquosa |
| WO2020223565A1 (en) * | 2019-05-01 | 2020-11-05 | Corvidia Therapeutics, Inc. | Anti-il-6 antibody formulation |
| AU2021224246A1 (en) * | 2020-02-21 | 2022-09-15 | Spitfire Pharma Llc | GLP-1R and GCGR agonists, formulations, and methods of use |
| RU2745814C1 (ru) * | 2020-06-05 | 2021-04-01 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция левилимаба и ее применение |
| EP4172351A4 (en) * | 2020-06-26 | 2024-08-14 | Trefoil Therapeutics, Inc. | RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THERAPEUTIC USES THEREOF |
| US11912764B2 (en) * | 2020-07-31 | 2024-02-27 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| WO2022037606A1 (en) * | 2020-08-19 | 2022-02-24 | Bio-Thera Solutions, Ltd. | Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| US20230073821A1 (en) * | 2021-08-27 | 2023-03-09 | International Business Machines Corporation | Antigen-binding proteins targeting coronavirus (cov) variants |
| JP2023042974A (ja) * | 2021-09-15 | 2023-03-28 | シスメックス株式会社 | 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体 |
| CN116554298A (zh) * | 2022-02-25 | 2023-08-08 | 南京工业大学 | 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法 |
| CA3265890A1 (en) * | 2022-09-30 | 2024-04-04 | Sonnet BioTherapeutics, Inc. | LOW-DOSE IL-6 FORMULATIONS AND THEIR METHODS OF USE |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| EP0795743A3 (en) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Method and apparatus for infra-red moisture measurement |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| ATE386802T1 (de) | 1997-06-12 | 2008-03-15 | Novartis Int Pharm Ltd | Künstliche antikörperpolypeptide |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| ATE439592T1 (de) | 1998-12-10 | 2009-08-15 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| CN1658836A (zh) | 2002-05-07 | 2005-08-24 | 控制传输系统公司 | 形成药物传递装置的方法 |
| CA2506230A1 (en) | 2002-11-15 | 2004-06-03 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
| US20040191243A1 (en) * | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| SG166768A1 (en) | 2003-12-23 | 2010-12-29 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| US20060204493A1 (en) | 2004-09-02 | 2006-09-14 | Genentech, Inc. | Heteromultimeric molecules |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2009521909A (ja) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体 |
| EP2004690A2 (en) | 2006-03-13 | 2008-12-24 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2008045140A1 (en) | 2006-05-19 | 2008-04-17 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
| AU2008216090A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein formulations containing sorbitol |
| KR101829776B1 (ko) | 2007-05-21 | 2018-02-19 | 앨더바이오 홀딩스 엘엘씨 | Ｉｌ-６에 대한 항체 및 이의 용도 |
| KR20160005378A (ko) * | 2007-09-14 | 2016-01-14 | 사노피 파스테르 바이오로직스, 엘엘씨 | 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물 |
| EA201000844A1 (ru) | 2007-11-21 | 2011-10-31 | Амген Инк. | Связывающие wise агенты и эпитопы |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| RU2537139C2 (ru) | 2008-01-15 | 2014-12-27 | Эбботт Гмбх Унд Ко.Кг | Порошковые белковые композиции и способы их получения |
| HUE026179T2 (en) | 2008-08-05 | 2016-05-30 | Novartis Ag | Preparations and methods for antibodies against complement C5 protein |
| EP2324930B1 (en) | 2008-09-12 | 2012-11-14 | KDF Co., Ltd. | Water-spouting device |
| WO2010039750A2 (en) * | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Transgenic plants with enhanced agronomic traits |
| US8992920B2 (en) * | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| KR20110091777A (ko) | 2008-11-26 | 2011-08-12 | 글락소 그룹 리미티드 | 폴리펩티드, 항체 가변 도메인 및 길항제 |
| US20120034212A1 (en) | 2009-01-29 | 2012-02-09 | Michael Bowen | Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory Diseases |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| CA2804185C (en) * | 2010-07-12 | 2017-03-21 | Covx Technologies Ireland Limited | Multifunctional antibody conjugates |
| WO2013086448A2 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc | IgG2 DISULFIDE ISOFORM SEPARATION |
| WO2013181495A2 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corporation | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
| WO2014039903A2 (en) * | 2012-09-07 | 2014-03-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| BR112015010360A8 (pt) * | 2012-11-08 | 2018-01-16 | Eleven Biotherapeutics Inc | antagonistas de il-6 e utilização dos mesmos. |
| SG11201510315TA (en) * | 2013-07-12 | 2016-01-28 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| UA122673C2 (uk) * | 2014-11-07 | 2020-12-28 | Елевен Байотерапьютікс, Інк. | Антитіло, що специфічно зв'язується з людським il-6 |
| WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
-
2017
- 2017-02-23 JP JP2018563405A patent/JP2019510078A/ja active Pending
- 2017-02-23 BR BR112018017031A patent/BR112018017031A2/pt not_active IP Right Cessation
- 2017-02-23 US US16/078,671 patent/US20190046642A1/en not_active Abandoned
- 2017-02-23 AU AU2017223687A patent/AU2017223687A1/en not_active Abandoned
- 2017-02-23 CN CN201780013039.9A patent/CN108718522A/zh active Pending
- 2017-02-23 CA CA3012350A patent/CA3012350A1/en not_active Abandoned
- 2017-02-23 EP EP17757207.0A patent/EP3419599A4/en active Pending
- 2017-02-23 AR ARP170100456A patent/AR107708A1/es unknown
- 2017-02-23 MX MX2018010032A patent/MX2018010032A/es unknown
- 2017-02-23 KR KR1020187027338A patent/KR20180116359A/ko not_active Withdrawn
- 2017-02-23 WO PCT/US2017/019131 patent/WO2017147293A1/en not_active Ceased
-
2021
- 2021-08-31 US US17/462,654 patent/US12048746B2/en active Active
-
2022
- 2022-03-31 JP JP2022058898A patent/JP2022084922A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018017031A2 (pt) | 2019-01-22 |
| JP2022084922A (ja) | 2022-06-07 |
| US20220241414A1 (en) | 2022-08-04 |
| EP3419599A4 (en) | 2019-09-11 |
| US20190046642A1 (en) | 2019-02-14 |
| KR20180116359A (ko) | 2018-10-24 |
| EP3419599A1 (en) | 2019-01-02 |
| US12048746B2 (en) | 2024-07-30 |
| JP2019510078A (ja) | 2019-04-11 |
| CN108718522A (zh) | 2018-10-30 |
| MX2018010032A (es) | 2019-03-11 |
| CA3012350A1 (en) | 2017-08-31 |
| WO2017147293A1 (en) | 2017-08-31 |
| AU2017223687A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107708A1 (es) | Formulaciones de antagonista de il-6 y sus usos | |
| BR112019002848A2 (pt) | anticorpo anti-lag-3 | |
| ES2965486T3 (es) | Formulaciones de anticuerpos anti-C5 de alta concentración | |
| JP2024102215A (ja) | プログラム死受容体１（ｐｄ－１）抗体の安定製剤およびその使用方法 | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
| MX391779B (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condición o enfermedad ocular. | |
| CL2019001049A1 (es) | Vacuna contra parvovirus porcino. | |
| PE20241305A1 (es) | Analogos de amilina | |
| HRP20191199T1 (hr) | Formulacije protutijela anti-prolaktinskog receptora | |
| RU2017103446A (ru) | УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ | |
| MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| MX2021005839A (es) | Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso. | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| EA201892443A1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови | |
| ZA202102986B (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| AR057239A1 (es) | Inmunoglobulinas | |
| AR117607A1 (es) | Formulaciones de anticuerpo líquidas de alta concentración | |
| CO2020001742A2 (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil | |
| CO2022009693A2 (es) | Formulación estable y de alta concentración del anticuerpo nimotuzumab | |
| Gupta | Ofloxacin-induced toxic epidermal necrolysis | |
| PE20241193A1 (es) | Formulaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |